P27kipl protein expression: An independent prognostic factor in rectal carcinoma stages I-III

Colorectal Disease

Volumn 1, Issue 6, 1999, Pages 315-323

  Pucciarelli, Salvatore ^a   Esposito, G ^a   Fassina, A ^a   Alaggio, R ^a   Masin, A ^a   Toppan, P ^a   Chieco Bianchi, L ^b   Lise, M ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b Univ̀ di Padova Policlinico ^*

Author keywords

Nm23; P27kipl; P53; Prognostic markers; Rectal carcinoma; VEGF

Indexed keywords

EID: 1842666628     PISSN: 14628910     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1463-1318.1999.00071.x     Document Type: Article

References (29)

1. Saclarides TJ. Endorectal ultrasound. Surg Clin North Am 1998; 72: 237-49.
2. Wiggers T, Arends JW, Schutte B, Volovics L, Bosman FT. A multivariate analysis of pathologic prognostic indicators in large bowel. Cancer 1988; 61: 386-95.
3. Jessup JM, Loda M, Bleday R. Clinical and molecular prognostic factors in sphincter-preserving surgery for rectal cancer. Semin Radiat Oncol 1998; 8: 54-69.
4. Lane DR. p53 guardian of the genome. Nature 1992; 358: 15-16.
5. Bertorelle R, Esposito G, Del Mistro A, Belluco C, Nitti D, Lise M, Chieco-Bianchi L. Association of p53 gene and protein alterations with metastases in colorectal cancer. Am J Surg Pathol 1995; 19: 463-71.
6. Wiggenraad R, Tamminga R, Blok P, Rouse R, Hermans J. The prognostic significance of p53 expression for survival and local control in rectal carcinoma treated with surgery and postoperative radiotherapy. Int J Radiat Oncol Biol Phys 1998; 41: 29-35.
7. Bell SM, Scott N, Cross D et al. Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer. Gastroenterology 1993; 104: 57-64.
8. Cordon-Cardo C. Mutation of cell cycle regulators. Biological and clinical implications for human neoplasia. Am J Pathol 1995; 147: 545-60.
9. kipl, a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes Dev 1994; 8: 9-22.
10. kipl) of cyclin-dependent kinase 4 activation. Cell 1994; 79: 487-96.
11. kipl protein: prognostic implications in primary breast cancer. Nat Med 1997; 3: 227-30.
12. 1a,b) invasive breast carcinomas. Cancer Res 1997; 57: 1259-63.
13. Esposito V, Baldi A, De Luca A et al. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res 1997; 57: 3381-5.
14. kipl is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res 1998; 58: 542-8.
15. Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup JM, Pagano M. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 1997; 3: 231-4.
16. Chung YS, Maeda K, Sowa M. Prognostic value of angiogenesis in gastro-intestinal tumors. Eur J Cancer 1996; 32A: 2501-5.
17. Steeg PS, Bevilacqua G, Kopper L, Thorgeirsson UP, Talmadge JE, Liotta LA, Sobel ME. Evidence for a novel gene associated with low tumor metastatic potential. J Natl Cancer Inst 1988; 80: 200.
18. AJCC American Joint Committee on Cancer (1997) Colon and Rectum. In: AJCC Cancer Staging Manual, 5th edn. (eds. Fleming DI, Cooper SJ, Henson ED et al.), pp. 83-90. Lippincott-Raven, Philadelphia.
19. Tomoda H, Kakeji Y. Immunohistochemical analysis of p53 in colorectal cancer regarding clinicopathological correlation and prognostic significance. J Surg Oncol 1995; 58: 125-8.
20. Diez M, Enriquez JM, Camuñas J, Gonzalez A, Gutierrez A, Mugüerza JM, Ruiz A, Granell J. Prediction of recurrence in B-C stages of colorectal cancer by p53 nuclear overexpression in comparison with standard pathological features. Eur J Surg Oncol 1995; 21: 635-9.
21. Leahy DT, Salman R, Mulcahy H, Sheahan K, O'Donoghue P, Parfrey NA. Prognostic significance of p53 abnormalities in colorectal carcinoma detected by PCR-SSCP and immunohistochemical analysis. J Pathol 1996; 180: 364-70.
22. kipl protein predicts poor outcome in patients with stage I-III colorectal cancer. SSO 51st Annual Cancer Symposium, March 26-29, San Diego, California. Abstract Book 1998; P55: 20.
23. Kumar H, Heer K, Lee PWR, Duthie GS, MacDonald AW, Greenman J, Kerin MJ, Monson JRT. Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer. Clin Cancer Res 1998; 4: 1279-85.
24. Frank RE, Saclarides TJ, Leurgans S, Speziale NJ, Drab EA, Rubin DB. Tumor angiogenesis as a predictor of recurrence and survival in patients with node-negative colon cancer. Ann Surg 1995; 222: 695-9.
25. Bossi P, Viale G, Lee AKC, Alfano RM, Coggi G, Bosari S. Angiogenesis in colorectal tumors: microvessel quantitation in adenomas and carcinomas with clinicopathological correlations. Cancer Res 1995; 55: 5049-53.
26. Cheah PY, Eu KW, Seow-Choen F. NM23-Hl immunostaining is inversely associated with tumour staging but not overall survival or disease recurrence in colorectal carcinomas. Br J Cancer 1998; 77: 1164-8.
27. Lindmark G. NM-23 Hl immunohistochemistry is not useful as predictor of metastatic potential of colorectal cancer. Br J Cancer 1996; 74: 1413-8.
28. Indinnimeo M, Giarnieri E, Stazi A, Chicchini C, Brozzetti S, Valli C, Carreca I, Vecchione A. Early stage human colorectal cancer: prognostic value of nm23-Hl protein overexpression. Cancer Lett 1997; 111: 1-5.
29. Berney CR, Yang J-L, Fisher RJ, Russel PJ, Crowe PJ. Overexpression of nm23 protein assessed by color video image analysis in metastatic colorectal cancer. Correlation with reduced patient survival. World J Surg 1998; 22: 484-90.